Joseph Hagan Biography and Net Worth

Director of Aurinia Pharmaceuticals

Joseph P. Hagan is the founder of GroundSwell Advisors LLC, where the company was founded in 2008 and the title held was Partner in 2009. Mr. Hagan is currently the Chief Executive Officer & Director at Regulus Therapeutics, Inc. since 2023. Former positions include Acting Chief Executive Officer at Unity Pharma, Director at Avidia, Inc., Director at ISB Accelerator Corp., Director at Ren Pharmaceuticals, Inc., Managing Director at Amgen Ventures LLC from 1998 to 2008, Director at Accelerator Services Corp, Director at Seredigm Corp., Independent Director at Zosano Pharma Corp from 2015 to 2022, Independent Director at Aurinia Pharmaceuticals, Inc. from 2018 to 2023, Head-Corporate Development at Amgen, Inc. from 1998 to 2008, and Chief Financial & Business Officer, Executive VP at Orexigen Therapeutics, Inc. from 2011 to 2015. Education includes an MBA from Northeastern University, conferred in 1998, and an undergraduate degree from the University of California San Diego, conferred in 1992.

What is Joseph P. Hagan's net worth?: The estimated net worth of Joseph P. Hagan is at least $3.99 million as of January 30th, 2025. Hagan owns 260,808 shares of Aurinia Pharmaceuticals stock worth more than $3,992,970 as of December 4th. This net worth approximation does not reflect any other investments that Hagan may own. Learn More about Joseph P. Hagan's net worth.
How do I contact Joseph P. Hagan?: The corporate mailing address for Hagan and other Aurinia Pharmaceuticals executives is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. Aurinia Pharmaceuticals can also be reached via phone at 250-708-4272 and via email at [email protected]. Learn More on Joseph P. Hagan's contact information.
Has Joseph P. Hagan been buying or selling shares of Aurinia Pharmaceuticals?: Joseph P. Hagan has not been actively trading shares of Aurinia Pharmaceuticals during the past quarter. Most recently, Joseph P. Hagan sold 272 shares of the business's stock in a transaction on Friday, May 19th. The shares were sold at an average price of $10.58, for a transaction totalling $2,877.76. Following the completion of the sale, the director now directly owns 11,961 shares of the company's stock, valued at $126,547.38. Learn More on Joseph P. Hagan's trading history.
Who are Aurinia Pharmaceuticals' active insiders?: Aurinia Pharmaceuticals' insider roster includes Jeffrey Bailey (Director), Matthew Donley (VP), Peter Greenleaf (CEO), Scott Habig (Chief Commercial Officer), Joseph Hagan (Director), Robert Huizinga (EVP), David Jayne (Director), Greg Keenan (Chief Medical Officer), Jill Leversage (Director), Michael Martin (Insider), Joseph Miller (CFO), Neil Solomons (Insider), and Kevin Tang (Director). Learn More on Aurinia Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Aurinia Pharmaceuticals?: In the last twelve months, Aurinia Pharmaceuticals insiders bought shares 3 times. They purchased a total of 1,300,000 shares worth more than $13,590,000.00. In the last twelve months, insiders at the biotechnology company sold shares 5 times. They sold a total of 343,898 shares worth more than $2,753,094.15. The most recent insider tranaction occured on August, 5th when Director Kevin Tang bought 200,000 shares worth more than $2,336,000.00. Insiders at Aurinia Pharmaceuticals own 12.2% of the company. Learn More about insider trades at Aurinia Pharmaceuticals.
Information on this page was last updated on 8/5/2025.

Joseph P. Hagan Insider Trading History at Aurinia Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/19/2023	Sell	272	$10.58	$2,877.76	11,961

Joseph P. Hagan Buying and Selling Activity at Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Company Overview

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Today's Range

Now: $15.31

$14.76

$15.35

50 Day Range

MA: $13.46

$11.05

$16.37

2 Week Range

Now: $15.31

$6.55

$16.48

Volume

1,073,274 shs

Average Volume

1,824,637 shs

Market Capitalization

$2.02 billion

P/E Ratio

27.34

Dividend Yield

N/A

Beta

1.42